C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activation

Clinical Immunology

Volumn 135, Issue 3, 2010, Pages 490-495

  van der Zee, P M ^a   Biro E ^b   Trouw, L A ^b   Ko, Y ^c   de Winter, R J ^a   Hack, C E ^d   Sturk, A ^c   Nieuwland, R ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Acute myocardial infarction; Complement activation; Microparticles

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4 BINDING PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; SERUM AMYLOID P;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MEMBRANE MICROPARTICLE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

C-REACTIVE PROTEIN; CELL SEPARATION; CELL-DERIVED MICROPARTICLES; COMPLEMENT ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 77951879538     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.01.002     Document Type: Article

References (38)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (2005) 1685-1695
2. Muscari A., Bozzoli C., Puddu G.M., Sangiorgi Z., Dormi A., Rovinetti C., Descovich G.C., and Puddu P. Association of serum C3 levels with the risk of myocardial infarction. Am. J. Med. 98 (1995) 357-364
3. Sabatine M.S., Morrow D.A., Jablonski K.A., Rice M.M., Warnica J.W., Domanski M.J., Hsia J., Gersh B.J., Rifai N., Ridker P.M., Pfeffer M.A., and Braunwald E. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 115 (2007) 1528-1536
4. Jenny N.S., Arnold A.M., Kuller L.H., Tracy R.P., and Psaty B.M. Serum amyloid P and cardiovascular disease in older men and women: results from the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 352-358
5. Kovanen P.T., Manttari M., Palosuo T., Manninen V., and Aho K. Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch. Intern. Med. 158 (1998) 1434-1439
6. Griselli M., Herbert J., Hutchinson W.L., Taylor K.M., Sohail M., Krausz T., and Pepys M.B. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J. Exp. Med. 190 (1999) 1733-1740
7. Pietila K., Harmoinen A., and Teppo A.M. Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant tissue type plasminogen activator. Ann. Med. 23 (1991) 529-535
8. Lagrand W.K., Niessen H.W., Wolbink G.J., Jaspars L.H., Visser C.A., Verheugt F.W., Meijer C.J., and Hack C.E. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 95 (1997) 97-103
9. Nijmeijer R., Krijnen P.A., Assink J., Klaarenbeek M.A., Lagrand W.K., Veerhuis R., Visser C.A., Meijer C.J., Niessen H.W., and Hack C.E. C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. Eur. J. Clin. Invest. 34 (2004) 803-810
10. Hill J.H., and Ward P.A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J. Exp. Med. 133 (1971) 885-900
11. Ito W., Schafer H.J., Bhakdi S., Klask R., Hansen S., Schaarschmidt S., Schofer J., Hugo F., Hamdoch T., and Mathey D. Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc. Res. 32 (1996) 294-305
12. Kaplan M.H., and Volanakis J.E. Interaction of C-reactive protein complexes with the complement system: I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J. Immunol. 112 (1974) 2135-2147
13. Mold C., Du Clos T.W., Nakayama S., Edwards K.M., and Gewurz H. C-reactive protein reactivity with complement and effects on phagocytosis. Ann. N.Y. Acad. Sci. 389 (1982) 251-262
14. Wolbink G.J., Brouwer M.C., Buysmann S., ten Berge I., and Hack C.E. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J. Immunol. 157 (1996) 473-479
15. Agrawal A., Shrive A.K., Greenhough T.J., and Volanakis J.E. Topology and structure of the C1q-binding site on C-reactive protein. J. Immunol. 166 (2001) 3998-4004
16. Schwalbe R.A., Dahlback B., Coe J.E., and Nelsestuen G.L. Pentraxin family of proteins interact specifically with phosphorylcholine and/or phosphorylethanolamine. Biochemistry 31 (1992) 4907-4915
17. Ying S.C., Gewurz A.T., Jiang H., and Gewurz H. Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. J. Immunol. 150 (1993) 169-176
18. Biró É., Nieuwland R., Tak P.P., Pronk L.M., Schaap M.C., Sturk A., and Hack C.E. Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann. Rheum. Dis. 66 (2007) 1085-1092
19. Tengvall P., Askendal A., and Lundstrom I. Complement activation by IgG immobilized on methylated silicon. J. Biomed. Mater. Res. 31 (1996) 305-312
20. Kim S.J., Gershov D., Ma X., Brot N., and Elkon K.B. I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J. Exp. Med. 196 (2002) 655-665
21. Zwart B., Ciurana C., Rensink I., Manoe R., Hack C.E., and Aarden L.A. Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity 37 (2004) 95-102
22. Nauta A.J., Trouw L.A., Daha M.R., Tijsma O., Nieuwland R., Schwaeble W.J., Gingras A.R., Mantovani A., Hack E.C., and Roos A. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur. J. Immunol. 32 (2002) 1726-1736
23. Gasser O., and Schifferli J.A. Microparticles released by human neutrophils adhere to erythrocytes in the presence of complement. Exp. Cell Res. 307 (2005) 381-387
24. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur. Heart J. 21 (2000) 1502-1513
25. Wolbink G.J., Bollen J., Baars J.W., ten Berge R.J., Swaak A.J., Paardekooper J., and Hack C.E. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J. Immunol. Methods 163 (1993) 67-76
26. Familian A., Zwart B., Huisman H.G., Rensink I., Roem D., Hordijk P.L., Aarden L.A., and Hack C.E. Chromatin-independent binding of serum amyloid P component to apoptotic cells. J. Immunol. 167 (2001) 647-654
27. Berckmans R.J., Nieuwland R., Böing A.N., Romijn F.P., Hack C.E., and Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb. Haemost. 85 (2001) 639-646
28. Biró É., Nieuwland R., and Sturk A. Measuring circulating cell-derived microparticles. J. Thromb. Haemost. 2 (2004) 1843-1844
29. Hack C.E., Paardekooper J., Smeenk R.J., Abbink J., Eerenberg A.J., and Nuijens J.H. Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3. An analysis with monoclonal antibodies. J. Immunol. 141 (1988) 1602-1609
30. Hoekzema R., Martens M., Brouwer M.C., and Hack C.E. The distortive mechanism for the activation of complement component C1 supported by studies with a monoclonal antibody against the "arms" of C1q. Mol. Immunol. 25 (1988) 485-494
31. Zadura A.F., Theander E., Blom A.M., and Trouw L.A. Complement inhibitor C4b binding protein in primary Sjögren's syndrome and its association with other disease markers. Scand. J. Immunol. 69 4 (2009) 374-380
32. Biró É., Lok C.A., Hack C.E., van der Post J.A., Schaap M.C., Sturk A., and Nieuwland R. Cell-derived microparticles and complement activation in preeclampsia versus normal pregnancy. Placenta 28 (2007) 928-935
33. Trouw L.A., Okroj M., Kupreishvili K., Landberg G., Johansson B., Niessen H.W.M., and Blom A.M. C4b-binding protein is present in affected areas of myocardial infarction during the acute inflammatory phase and covers a larger area than C3. Plos One 3 (2008) e2886
34. Sjoberg A.P., Trouw L.A., McGrath F.D., Hack C.E., and Blom A.M. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J. Immunol. 176 (2006) 7612-7620
35. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340 (1999) 448-454
36. Trouw L.A., Bengtsson A.A., Gelderman K.A., Dahlbäck B., Sturfelt G., and Blom A.M. C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J. Biol. Chem. 282 (2007) 28540-28548
37. Sjöberg A.P., Trouw L.A., and Blom A.M. Complement activation and inhibition: a delicate balance. Trends Immunol. 30 2 (2009 Feb) 83-90
38. Sjöwall C., Wetterö J., Bengtsson T., Askendal A., Almroth G., Skogh T., and Tengvall P. Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction. Biochem. Biophys. Res. Commun. 352 1 (2007 Jan 5) 251-258